TargetMol

BMS-212122

Product Code:
 
TAR-T30506
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30506-1mg1mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30506-5mg5mg£736.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30506-10mg10mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30506-25mg25mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30506-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30506-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30506-500mg500mg£4,006.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BMS-212122 is an effective microsomal triglyceride transfer protein inhibitor (MTP inhibitor). MS-212122 was more effective than BMS-201038 in lowering blood lipid (cholesterol, VLDL/LDL, TG) in hamsters and crab-eating monkeys. Treatment with BMS-212122 resulted in a rapid decrease in plasma lipid levels and a significant decrease in lipid content and mononuclear cell-derived (CD68+) cells in atherosclerotic plaques compared to baseline and diet-diet controls.
CAS:
194213-64-4
Formula:
C43H36F6N4O2
Molecular Weight:
754.777
Pathway:
Metabolism
Purity:
0.98
SMILES:
Cc1nc2c(NC(=O)c3ccccc3-c3ccc(cc3)C(F)(F)F)c(C)ccc2n1CCCCC1(C(=O)NCC(F)(F)F)c2ccccc2-c2ccccc12
Target:
CETP

References

1. Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013 Mar;227(1):125-9. doi: 10.1016/j.atherosclerosis.2012.12.026. PubMed PMID: 23332773; PubMed Central PMCID: PMC4047651. 2. Robl JA, Sulsky R, Sun CQ, Simpkins LM, Wang T, Dickson JK Jr, Chen Y, Magnin DR, Taunk P, Slusarchyk WA, Biller SA, Lan SJ, Connolly F, Kunselman LK, Sabrah T, Jamil H, Gordon D, Harrity TW, Wetterau JR. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001 Mar 15;44(6):851-6. PubMed PMID: 11300866. 3. Dikkers A, Annema W, de Boer JF, Iqbal J, Hussain MM, Tietge UJ. Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice. J Lipid Res. 2014 May;55(5):816-25. doi: 10.1194/jlr.M042986. PubMed PMID: 24511105; PubMed Central PMCID: PMC3995460.